Logo image of ZYNE

ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZYNE - US98986X1090 - Common Stock

1.3 USD
+0.03 (+2.36%)
Last: 10/10/2023, 8:00:03 PM
1.3015 USD
+0 (+0.12%)
After Hours: 10/10/2023, 8:00:03 PM
Fundamental Rating

2

Taking everything into account, ZYNE scores 2 out of 10 in our fundamental rating. ZYNE was compared to 192 industry peers in the Pharmaceuticals industry. While ZYNE seems to be doing ok healthwise, there are quite some concerns on its profitability. ZYNE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ZYNE has reported negative net income.
In the past year ZYNE has reported a negative cash flow from operations.
In the past 5 years ZYNE always reported negative net income.
In the past 5 years ZYNE always reported negative operating cash flow.
ZYNE Yearly Net Income VS EBIT VS OCF VS FCFZYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

ZYNE has a worse Return On Assets (-92.85%) than 78.47% of its industry peers.
Looking at the Return On Equity, with a value of -129.50%, ZYNE is doing worse than 67.94% of the companies in the same industry.
Industry RankSector Rank
ROA -92.85%
ROE -129.5%
ROIC N/A
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
ZYNE Yearly ROA, ROE, ROICZYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80

1.3 Margins

ZYNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYNE Yearly Profit, Operating, Gross MarginsZYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -50K -100K -150K -200K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ZYNE has more shares outstanding
There is no outstanding debt for ZYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZYNE Yearly Shares OutstandingZYNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ZYNE Yearly Total Debt VS Total AssetsZYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

ZYNE has an Altman-Z score of -8.88. This is a bad value and indicates that ZYNE is not financially healthy and even has some risk of bankruptcy.
ZYNE has a Altman-Z score of -8.88. This is in the lower half of the industry: ZYNE underperforms 74.64% of its industry peers.
ZYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.88
ROIC/WACCN/A
WACCN/A
ZYNE Yearly LT Debt VS Equity VS FCFZYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 3.43 indicates that ZYNE has no problem at all paying its short term obligations.
ZYNE has a Current ratio (3.43) which is in line with its industry peers.
ZYNE has a Quick Ratio of 3.43. This indicates that ZYNE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.43, ZYNE is in line with its industry, outperforming 52.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 3.43
ZYNE Yearly Current Assets VS Current LiabilitesZYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.98% over the past year.
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.48% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYNE Yearly Revenue VS EstimatesZYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
ZYNE Yearly EPS VS EstimatesZYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZYNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZYNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYNE Price Earnings VS Forward Price EarningsZYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYNE Per share dataZYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

ZYNE's earnings are expected to grow with 15.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.85%
EPS Next 3Y15.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYNERBA PHARMACEUTICALS INC

NASDAQ:ZYNE (10/10/2023, 8:00:03 PM)

After market: 1.3015 +0 (+0.12%)

1.3

+0.03 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-13 2023-11-13/bmo
Inst Owners0.03%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change0%
Market Cap70.12M
Revenue(TTM)N/A
Net Income(TTM)-37.58M
Analysts48.89
Price Target1.28 (-1.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.52%
Min EPS beat(2)-8.36%
Max EPS beat(2)-4.68%
EPS beat(4)2
Avg EPS beat(4)1.11%
Min EPS beat(4)-8.36%
Max EPS beat(4)12.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-78.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)145%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.91%
Revenue NQ rev (1m)99900%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.85%
ROE -129.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.34%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 3.43
Altman-Z -8.88
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)101.27%
Cap/Depr(5y)138.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.8%
EBIT Next 3Y1.94%
EBIT Next 5Y31.42%
FCF growth 1Y9.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.18%
OCF growth 3YN/A
OCF growth 5YN/A

ZYNERBA PHARMACEUTICALS INC / ZYNE FAQ

What is the fundamental rating for ZYNE stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZYNE.


Can you provide the valuation status for ZYNERBA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ZYNERBA PHARMACEUTICALS INC (ZYNE). This can be considered as Overvalued.


Can you provide the profitability details for ZYNERBA PHARMACEUTICALS INC?

ZYNERBA PHARMACEUTICALS INC (ZYNE) has a profitability rating of 0 / 10.


Can you provide the financial health for ZYNE stock?

The financial health rating of ZYNERBA PHARMACEUTICALS INC (ZYNE) is 6 / 10.


Can you provide the expected EPS growth for ZYNE stock?

The Earnings per Share (EPS) of ZYNERBA PHARMACEUTICALS INC (ZYNE) is expected to decline by -2.82% in the next year.